Targeted therapies are the state of the art in oncology today. and every year new Tumor-associated antigens (TAAs) are developed for preclinical research and clinical trials. but few of them really change the therapeutic scenario. Difficulties. https://www.sonosenzaparole.com/product-category/lp/